非小细胞肺癌多耐药基因产物(P-gp)表达与多种预后因素的关系  

The Expression of Multi-drug Resistance Gene in Non-small Cell Lung Cancer and Prognosis Factor Analysis

作　　者：李宁[1] 余琦[1] 孙洋[1] 白雪娟[1] 周惠芹[1] 刘成龙[1] 

机构地区：[1]中国人民解放军第309医院病理科,北京100091

出　　处：《标记免疫分析与临床》2010年第5期318-320,共3页Labeled Immunoassays and Clinical Medicine

摘　　要：探讨非小细胞肺癌(NSCLC)多药耐药基因-1(MDR-1)产物P-糖蛋白(P-gp)在术前未经治疗的非小细胞肺癌组织中的表达及与多种预后因素间的关系。采用免疫组化法检测P-gp在56例NSCLC组织中的表达及其与性别、病理类型、病理分级、淋巴结状况、细胞增殖指数(Ki67)、肿瘤细胞修复能力(TOPOⅡ、MGMT)、表皮生长因子受体(EGFR)、肿瘤的免疫状态(HSP70)以及参与肿瘤恶变、凋亡及转移的癌基因和抑癌基因(P53、Bcl-2、C-erb-2、MDM2)的相关性。结果显示,P-gp在非小细胞肺癌组织中的阳性表达率是53.6%(30/56),P-gp与TOPOⅡ之间(r=0.279,P=0.037)、P-gp与EG-FR之间(r=0.320,P=0.016)、P-gp与HSP70之间(r=0.279,P=0.037)以及P-gp与C-erb2之间(r=0.249,P=0.043)有相关性。结论:非小细胞肺癌组织中P-gp的表达与多种基因的表达密切相关。采用MDR-1逆转剂可增加非小细胞肺癌的化疗敏感性,行多基因联合检查可为预测非小细胞肺癌预后及指导化疗提供实验依据。To investigate the expression of multi-drug resistance gene in non-small cell lung cancer（NSCLC） and to analysis its relationship with several prognostic factors and cancer gene in resected NSCLC.The expression of P-glucoprotein,Ki67,TOPOⅡ,MGMT,EGFR,HSP70,P53,Bcl-2,C-erb2 and MDM2 in NSCLC were detected by immunohistochemistry.The results showed that the positive rates of P-gp in tumor tissues were 53.6%.The expression of P-gp was correlated with those of TOPOⅡ（r=0.279,P=0.037）,EGFR（r=0.320,P=0.016）,HSP70（r=0.279,P=0.037） and C-erb2（r= 0.249,P=0.043）.The expression of P-gp was closely correlated with many genes in non-small cell lung cancer,and it offers experiment bases to reversion gene therapy and multi-gene detection to predict prognosis and supervise chemotherapy.

关 键 词：非小细胞肺癌 免疫组织化学 多药耐药 

分 类 号：R734.2[医药卫生—肿瘤]